CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2016--
Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome
therapeutics platform company, today announced it will present at the
UBS Global Healthcare Conference on Tuesday, May 24. The presentation
will take place at the Grand Hyatt Hotel in New York, NY at 8:30 a.m. ET.
Live audio webcast will be available under the Investors and Media
section of Seres’ website. A replay of the presentation will become
available approximately one hour after the event and will be archived
for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome,
where the natural state of bacterial diversity and function is
imbalanced. Seres’ most advanced program, SER-109, has successfully
completed a Phase 1b/2 study demonstrating a clinical benefit in
patients with recurring Clostridium difficile infection (CDI) and
is currently being evaluated in a Phase 2 study in recurring CDI. The
FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy,
designations. Seres’ second clinical candidate, SER-287, is being
evaluated in a Phase 1b study in patients with mild-to-moderate
ulcerative colitis (UC). For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160517005598/en/
Source: Seres Therapeutics
IR and PR Contact:
Seres
Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor
Relations and Corporate Communications
Ctanzi@serestherapeutics.com
